JP7670698B2 - 認知症におけるｇｌｐ－１受容体作動薬 - Google Patents

認知症におけるｇｌｐ－１受容体作動薬 Download PDF

Info

Publication number
JP7670698B2
JP7670698B2 JP2022521146A JP2022521146A JP7670698B2 JP 7670698 B2 JP7670698 B2 JP 7670698B2 JP 2022521146 A JP2022521146 A JP 2022521146A JP 2022521146 A JP2022521146 A JP 2022521146A JP 7670698 B2 JP7670698 B2 JP 7670698B2
Authority
JP
Japan
Prior art keywords
glp
dementia
receptor agonist
pharmaceutical composition
semaglutide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500032A (ja
JP2023500032A5 (https=
Inventor
フリードリヒ、サラ
クリスティーン シム ハンセン、シャーロット
ベール クヌーセン、ロデ
セシェル、アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7670698(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2023500032A publication Critical patent/JP2023500032A/ja
Publication of JP2023500032A5 publication Critical patent/JP2023500032A5/ja
Priority to JP2024211204A priority Critical patent/JP2025027130A/ja
Application granted granted Critical
Publication of JP7670698B2 publication Critical patent/JP7670698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022521146A 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬 Active JP7670698B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024211204A JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207501.8 2019-11-06
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20186623.3 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211204A Division JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Publications (3)

Publication Number Publication Date
JP2023500032A JP2023500032A (ja) 2023-01-04
JP2023500032A5 JP2023500032A5 (https=) 2023-11-14
JP7670698B2 true JP7670698B2 (ja) 2025-04-30

Family

ID=73172681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521146A Active JP7670698B2 (ja) 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Country Status (19)

Country Link
US (4) US20220280612A1 (https=)
EP (2) EP4414031A3 (https=)
JP (2) JP7670698B2 (https=)
KR (1) KR20220110731A (https=)
CN (1) CN114728042A (https=)
AU (1) AU2020377469A1 (https=)
BR (1) BR112022007721A2 (https=)
CA (1) CA3154744A1 (https=)
ES (1) ES2984177T3 (https=)
HR (1) HRP20241052T1 (https=)
HU (1) HUE067514T2 (https=)
IL (1) IL291876A (https=)
MA (1) MA57599B1 (https=)
MX (1) MX2022004779A (https=)
PH (1) PH12022550842A1 (https=)
PL (1) PL4054620T3 (https=)
RS (1) RS65780B1 (https=)
TW (1) TWI890704B (https=)
WO (1) WO2021089678A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
KR20240123816A (ko) 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503526A (ja) 2010-12-16 2014-02-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
JP2019500369A (ja) 2015-12-23 2019-01-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ−１ｒアゴニスト

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503526A (ja) 2010-12-16 2014-02-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
JP2019500369A (ja) 2015-12-23 2019-01-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ−１ｒアゴニスト

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUCKLEY, STEPHEN T. et al.，Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist，SCIENCE TRANSLATIONAL MEDICINE，2018年，Vol 10, Issue 467，p. 1-13
DAY, Stephen M. and MAO, Tao，Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease Insight，Neurosci. Bull.，2019年03月07日，volume 35，pages934-936
FEMMINELLA, Grazia Daniela et al.，Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)，Trials，2019年04月03日，volume 20, Article number: 191，p. 1-10
Front Endocrinol (Lausanne).，The Discovery and Development of Liraglutide and Semaglutide，KNUDSEN, Lotte Bjerre et al.，2019年04月12日，10: 155，p.1-2, p. 5-6, p. 11, p. 22-24
TALBOT, Konrad，Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs，Neurodegener Dis Manag. Author manuscript available in PMC，2014年，4(1)，p. 31-40

Also Published As

Publication number Publication date
US20230302094A1 (en) 2023-09-28
HRP20241052T1 (hr) 2024-11-08
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
EP4054620C0 (en) 2024-05-29
CA3154744A1 (en) 2021-05-14
HUE067514T2 (hu) 2024-10-28
EP4414031A2 (en) 2024-08-14
JP2023500032A (ja) 2023-01-04
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
MA57599B1 (fr) 2024-06-28
CN114728042A (zh) 2022-07-08
TW202519256A (zh) 2025-05-16
US12539326B2 (en) 2026-02-03
KR20220110731A (ko) 2022-08-09
ES2984177T3 (es) 2024-10-29
US20220280612A1 (en) 2022-09-08
TW202118509A (zh) 2021-05-16
AU2020377469A1 (en) 2022-04-28
MX2022004779A (es) 2022-06-14
EP4054620B1 (en) 2024-05-29
JP2025027130A (ja) 2025-02-26
IL291876A (en) 2022-06-01
TWI890704B (zh) 2025-07-21
US20250099549A1 (en) 2025-03-27
US20240207364A1 (en) 2024-06-27
PL4054620T3 (pl) 2024-10-14
PH12022550842A1 (en) 2023-10-09
BR112022007721A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
JP7670698B2 (ja) 認知症におけるｇｌｐ－１受容体作動薬
Watson et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP2005516968A (ja) Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
KR20180081807A (ko) 알츠하이머 질환 및 관련 장애의 치료 방법
JP2018514555A (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
EP3684348A1 (en) Treatment of disease with esters of selective rxr agonists
CN113950328A (zh) 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
BR112019023557A2 (pt) Composição farmacêutica compreendendo inibidor de pde9
JP2025507858A (ja) 筋萎縮性側索硬化症の治療のための、ｃｙｐ ｐ４５０又はトランスポーター基質を伴う胆汁酸及びフェニルブチレート
JP2002053493A (ja) 全身性エリテマトーデスおよび炎症性腸疾患を治療するための成長ホルモン分泌促進物質の使用
US12552763B2 (en) Methods of protecting against neurodegeneration
US20080207716A1 (en) Formulations and Dosing Regiment for Ppar-Alpha Modulators
TWI923289B (zh) 用於失智症之glp-1受體促效劑
EA052078B1 (ru) Агонисты рецептора glp-1 при лечении деменции
EA046973B1 (ru) Агонисты рецептора glp-1 при лечении деменции
HK40075453A (en) Semaglutide in the treatment of alzheimer's dementia
JP2002220345A (ja) 脂肪肝改善剤
CA2753754C (en) Methods for treating schizophrenia
CN112789044A (zh) 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
WO2025188734A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2026093543A1 (en) Glp1r agonist and pcsk9 inhibitor combination therapy

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250417

R150 Certificate of patent or registration of utility model

Ref document number: 7670698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150